Czech deal for Nymox's Alzheimer's test:
This article was originally published in Clinica
Executive Summary
Maywood, New Jersey biotech firm Nymox Pharmaceutical has signed a marketing and distribution agreement for Prague-based KlinLab to sell its AlzheimAlert product in the Czech Republic. The test, which measures a particular biomarker in patients' urine, is offered as an aid to the diagnosis of Alzheimer's disease, and was recently CE-marked (see Clinica No 1135, p 23), although a premarket approval application was rejected in the US last year, and the company has filed an amended application.